Literature DB >> 10803470

Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome.

L M Fatti1, B Bottasso, C Invitti, R Coppola, F Cavagnini, P M Mannucci.   

Abstract

Patients with active Cushing's syndrome have an increased thrombotic tendency. We chose to reassess the mechanism underlying the thrombophilic state associated with this clinical condition using sensitive markers of coagulation and fibrinolysis activation in 17 patients with active disease. The results were compared with those obtained in 12 Cushing's patients successfully treated by surgery and in 20 normal individuals. The general pattern of results in patients with active disease was the finding of increased levels of von Willebrand factor (VWF: Ag), a marker of enhanced metabolic function of endothelial cells (VWF:Ag 181 +/- 42 vs 110 +/- 43, p<0.001 in normal subjects), accompanied by signs of heightened thrombin and plasmin generation, expressed by high levels of thrombin-antithrombin (TAT 5.59+/-3.6 vs 3.06+/-0.92 ng/ml in controls, p<0.01) and plasmin-antiplasmin complexes (PAP 407+/-176 vs 245+/-67 ng/ml in controls, p<0.01). VWF:Ag and TAT values were significantly higher in hypertensive than in normotensive patients with active disease (205+/-40 vs 155+/-26 U/dl, p<0.05 and 7.49+/-3.7 vs 3.45+/-1.8, p<0.01, respectively). Plasma levels of plasminogen activator inhibitor type 1 were higher, though not to a statistically significant extent, in patients with active disease compared to controls (12.8+/-12.3 vs 5.6+/-7.4 IU/ml, NS) and positively correlated with body mass index (r=0.66, p<0.01). After surgical control of Cushing's syndrome, there was a partial or complete reversal of the abnormalities to values similar to those found in normal individuals. Our data suggest that the thrombophilic state present in patients with active Cushing's syndrome is related to an enhanced metabolic function of endothelial cells; this in turn may be caused by an heightened production of thrombin with secondary hyperfibrinolysis. Primary prophylaxis with anticoagulants is recommended in these patients when they are exposed to a thrombophilic condition such as surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803470     DOI: 10.1007/BF03343697

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   5.467


  29 in total

1.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

2.  Risk factors for brain infarction in patients with Cushing's disease. Case reports.

Authors:  T Mizokami; K Okamura; K Sato; T Kuroda; S Sadoshima; M Fujishima
Journal:  Angiology       Date:  1996-10       Impact factor: 3.619

3.  Operative treatment, surgical approach, and related complications in 195 operations upon the adrenal glands.

Authors:  M Blichert-Toft; A Bagerskov; K Lockwood; E Hasner
Journal:  Surg Gynecol Obstet       Date:  1972-08

4.  Recurrent thromboembolism as a hallmark of Cushing's syndrome.

Authors:  A La Brocca; M Terzolo; A Pia; P Paccotti; P De Giuli; A Angeli
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

5.  von Willebrand factor and endothelial damage in essential hypertension.

Authors:  A D Blann; T Naqvi; M Waite; C N McCollum
Journal:  J Hum Hypertens       Date:  1993-04       Impact factor: 3.012

6.  Altered morning and nighttime pulsatile corticotropin and cortisol release in polycystic ovary syndrome.

Authors:  C Invitti; M De Martin; G Delitala; J D Veldhuis; F Cavagnini
Journal:  Metabolism       Date:  1998-02       Impact factor: 8.694

7.  Glucocorticoids inhibit plasminogen activator production by endothelial cells.

Authors:  W E Laug
Journal:  Thromb Haemost       Date:  1983-12-30       Impact factor: 5.249

8.  Further studies on the hypercoagulable state of patients with Cushing's syndrome.

Authors:  G M Patrassi; R Dal Bo Zanon; M Boscaro; S Martinelli; A Girolami
Journal:  Thromb Haemost       Date:  1985-08-30       Impact factor: 5.249

9.  Enzyme-linked immunosorbent assay of human factor VII based upon a monoclonal antibody that recognizes the native conformation of the protein.

Authors:  R Coppola; S Tombesi; F Valentini; S Alborali; A Albertini; P M Mannucci
Journal:  Thromb Res       Date:  1992-11-01       Impact factor: 3.944

10.  Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state.

Authors:  R Dal Bo Zanon; L Fornasiero; M Boscaro; G Cappellato; F Fabris; A Girolami
Journal:  Thromb Haemost       Date:  1982-04-30       Impact factor: 5.249

View more
  19 in total

1.  Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?

Authors:  Mattia Barbot; Viviana Daidone; Marialuisa Zilio; Nora Albiger; Linda Mazzai; Maria Teresa Sartori; Anna Chiara Frigo; Massimo Scanarini; Luca Denaro; Marco Boscaro; Sandra Casonato; Filippo Ceccato; Carla Scaroni
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

2.  A venous thromboembolism risk assessment model for patients with Cushing's syndrome.

Authors:  Marialuisa Zilio; Linda Mazzai; Maria Teresa Sartori; Mattia Barbot; Filippo Ceccato; Viviana Daidone; Alessandra Casonato; Graziella Saggiorato; Franco Noventa; Laura Trementino; Paolo Prandoni; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Endocrine       Date:  2015-06-26       Impact factor: 3.633

3.  Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease.

Authors:  Francesca Pecori Giraldi; Alberto G Ambrogio; Letizia M Fatti; Valentina Rubini; Giovanna Cozzi; Massimo Scacchi; Augusto B Federici; Francesco Cavagnini
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

4.  Coagulation Profile in Patients with Different Etiologies for Cushing Syndrome: A Prospective Observational Study.

Authors:  Amit Tirosh; Maya Lodish; Charalampos Lyssikatos; Elena Belyavskaya; Richard A Feelders; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2017-02-22       Impact factor: 2.936

Review 5.  Clinical consequences of Cushing's syndrome.

Authors:  Elena Valassi; Iris Crespo; Alicia Santos; Susan M Webb
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 6.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

7.  Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers.

Authors:  Darko Kastelan; Tina Dusek; Ivana Kraljevic; Ozren Polasek; Zlatko Giljevic; Mirsala Solak; Silva Zupancic Salek; Jozo Jelcic; Izet Aganovic; Mirko Korsic
Journal:  Endocrine       Date:  2009-04-21       Impact factor: 3.633

8.  Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?

Authors:  S Koutroumpi; L Spiezia; N Albiger; M Barbot; M Bon; S Maggiolo; S Gavasso; P Simioni; A Frigo; F Mantero; C Scaroni
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

Review 9.  The coagulation system in endocrine disorders: a narrative review.

Authors:  A Squizzato; V E A Gerdes; W Ageno; H R Büller
Journal:  Intern Emerg Med       Date:  2007-07-09       Impact factor: 3.397

10.  Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile.

Authors:  S Koutroumpi; V Daidone; M T Sartori; M G Cattini; N M Albiger; G Occhi; S Ferasin; A Frigo; F Mantero; A Casonato; C Scaroni
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.